Clinical population pharmacokinetics and toxicodynamics of linezolid

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2334-2343

  Boak, Lauren M ^a,f   Rayner, Craig R ^a,b   Grayson, M Lindsay ^a,c   Paterson, David L ^d,g   Spelman, Denis ^a   Khumra, Sharmila ^a,c   Capitano, Blair ^d,h   Forrest, Alan ^e   Li, Jian ^a   Nation, Roger L ^a   Bulitta, Jurgen B ^a,e  

^a MONASH UNIVERSITY   (Australia)

^b D3 Medicine LLC   (United States)

^c AUSTIN HOSPITAL   (Australia)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOXICITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; TOXICODYNAMICS; TREATMENT DURATION; TURNOVER TIME; YOUNG ADULT;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84896989728     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01885-13     Document Type: Article

References (44)

1. Wilcox MH. 2003. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl 2):ii27-ii35. http://dx.doi.org/10.1093/jac/dkg251. (Pubitemid 36622109)
2. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. 2003. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36:159-168. http://dx.doi.org/10.1086/345744. (Pubitemid 36143412)
3. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. 2001. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos. 22:91-97. http://dx.doi.org/10.1002/bdd. 255. (Pubitemid 34030882)
4. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. 2003. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother. 51:1239-1246. http://dx.doi.org/10.1093/jac/dkg180. (Pubitemid 36622080)
5. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J. 2003. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agents Chemother. 47:1824-1831. http://dx.doi.org/10.1128/AAC.47.6. 1824-1831.2003. (Pubitemid 36637801)
6. Attassi K, Hershberger E, Alam R, Zervos MJ. 2002. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34:695-698. http://dx.doi.org/10.1086/338403. (Pubitemid 34165334)
7. Orrick JJ, Johns T, Janelle J, Ramphal R. 2002. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin. Infect. Dis. 35:348-349. http://dx.doi.org/10.1086/341310. (Pubitemid 34800291)
8. Grau S, Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Alvarez-Lerma F. 2005. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J. Antimicrob. Chemother. 56:440-441. http://dx.doi.org/10.1093/jac/dki202. (Pubitemid 41158548)
9. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. 2010. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int. J. Antimicrob. Agents 36:179-181. http://dx.doi.org/10.1016/j.ijantimicag.2010.02. 019.
10. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. 2006. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother. 50:1599-1602. http://dx.doi.org/10.1128/ AAC.50.4.1599-1602.2006.
11. Forrest A, Rayner CR, Meager AK, Birmingham MC, Schentag JJ. 2000. Pharmacostatistical modelling of hematologic effects of linezolid in seriously-ill patients, abstr 283. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
12. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I. 2011. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob. Agents Chemother. 55:1867-1873. http://dx.doi.org/10.1128/ AAC.01185-10.
13. Green SL, Maddox JC, Huttenbach ED. 2001. Linezolid and reversible myelosuppression. JAMA 285:1291. http://dx.doi.org/10.1001/jama.285.10.1291.
14. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. 2003. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37:517-520. http://dx.doi.org/10.1345/aph.1C361. (Pubitemid 36389660)
15. Pascoalinho D, Vilas MJ, Coelho L, Moreira P. 2011. Linezolid-related immune-mediated severe thrombocytopenia. Int. J. Antimicrob. Agents 37:88-89. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.001.
16. Boak LM, Li J, Nation RL, Rayner CR. 2006. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed. Chromatogr. 20:782-786. http://dx.doi.org/10.1002/bmc.597. (Pubitemid 44203174)
17. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. 2005. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br. J. Clin. Pharmacol. 59:189-198. http://dx.doi.org/10.1111/j. 1365-2125.2004.02321.x. (Pubitemid 40208855)
18. Plock N, Buerger C, Joukhadar C, Kljucar S, Kloft C. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816-1823. http://dx.doi.org/10.1124/dmd.106.013755. (Pubitemid 47481573)
19. Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG. 2013. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob. Agents Chemother. 57:498-507. http://dx.doi.org/10.1128/AAC.01354- 12.
20. Krzyzanski W. 2011. Interpretation of transit compartments pharmaco-dynamic models as lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 38:179-204. http://dx.doi.org/10.1007/s10928-010- 9183-z.
21. Muller U, Kulinna J, Luber J, Hebestreit HP, Mayer M, Kempgens U, Queisser W. 1977. In vivo study of platelet kinetics by 75Se-methionine in different haematological disorders. Blut 34:31-38. http://dx.doi.org/10.1007/ BF00997036. (Pubitemid 8017020)
22. Najean Y, Ardaillou N, Dresch C. 1969. Platelet lifespan. Annu. Rev. Med. 20:47-62. http://dx.doi.org/10.1146/annurev.me.20.020169.000403.
23. Shulman NR, Jordan JV, Jr, Falchuk S. 1985. A normal fixed-loss component of platelet utilization accounting for short survival of transfused platelets. Ann. N. Y. Acad. Sci. 459:367-374. http://dx.doi.org/10.1111/j.1749-6632.1985. tb20846.x. (Pubitemid 16055222)
24. Friberg LE, Karlsson MO. 2003. Mechanistic models for myelosuppression. Invest. New Drugs 21: 183-194. http://dx.doi.org/10.1023/A:1023573429626. (Pubitemid 36859318)
25. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211. http://dx.doi.org/10.1208/s12248-011- 9257-x.
26. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 13:212-226. http://dx.doi.org/10.1208/ s12248-011-9258-9.
27. Devine BJ. 1974. Case number 25: gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
28. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41. http://dx.doi.org/10.1159/000180580.
29. Matthews I, Kirkpatrick C, Holford N. 2004. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br. J. Clin. Pharmacol. 58:8-19. http://dx.doi.org/10.1111/j.1365-2125.2004.02114.x. (Pubitemid 38901461)
30. Bulitta JB, Duffull SB, Landersdorfer CB, Kinzig M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F. 2009. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Diagn. Microbiol. Infect. Dis. 65:130-141. http://dx.doi.org/10. 1016/j.diagmicrobio.2009.06.018.
31. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094708. (Pubitemid 351738156)
32. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507. http://dx.doi.org/10.1128/AAC.01477-06. (Pubitemid 47047329)
33. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036-2049. http://dx.doi.org/10.1007/s11095-006- 9067-5.
34. Charlson M, Szatrowski TP, Peterson J, Gold J. 1994. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47:1245-1251. http://dx.doi.org/10.1016/0895-4356(94)90129-5. (Pubitemid 24361532)
35. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478. http://dx.doi.org/10.1007/BF01061691. (Pubitemid 24025269)
36. Sharma A, Slugg PH, Hammett JL, Jusko WJ. 1998. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm. Res. 15:1782-1786. http://dx.doi.org/10.1023/A:1011977116543. (Pubitemid 28524592)
37. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553. http://dx.doi.org/10.1128/AAC.47.2.548-553.2003. (Pubitemid 36158080)
38. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423. http://dx.doi.org/10.2165/00003088-200342150-00007. (Pubitemid 38054365)
39. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2005. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49:5024-5032. http://dx.doi.org/10.1128/AAC.49.12.5024-5032.2005. (Pubitemid 41778916)
40. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. 2009. Multiplepool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother. Pharmacol. 63:1035-1048. http://dx.doi.org/10.1007/s00280-008-0828-1.
41. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K. 2013. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. 68:2128-2133. http://dx.doi.org/10.1093/jac/dkt133.
42. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. 2013. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob. Agents Chemother. 57:1144-1149. http://dx.doi.org/10.1128/ AAC.01453-12.
43. Tsuji BT, Brown T, Parasrampuria R, Brazeau DA, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Hanna D, Bulitta JB. 2012. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob. Agents Chemother. 56:3712-3719. http://dx.doi.org/10.1128/AAC.05453-11.
44. Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D. 2012. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J. Antimicrob. Chemother. 67:2182-2190. http://dx.doi.org/10.1093/jac/dks201.